110 related articles for article (PubMed ID: 25347368)
21. [Recrudescent prostate cancer with a low serum PSA level and a high serum CEA level treated with docetaxel : a case report].
Fujita M; Goto T; Uchida K; Saiki S; Arima R
Hinyokika Kiyo; 2013 Mar; 59(3):183-8. PubMed ID: 23633635
[TBL] [Abstract][Full Text] [Related]
22. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
[TBL] [Abstract][Full Text] [Related]
23. Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer.
Fenioux C; Louvet C; Charton E; Rozet F; Ropert S; Prapotnich D; Barret E; Sanchez-Salas R; Mombet A; Cathala N; Joulia ML; Molitor JL; Henriques J; Bonnetain F; Cathelineau X; Bennamoun M
BJU Int; 2019 Feb; 123(2):300-306. PubMed ID: 30099821
[TBL] [Abstract][Full Text] [Related]
24. Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
Kosaka T; Hongo H; Oya M
BMC Cancer; 2019 Jun; 19(1):562. PubMed ID: 31185946
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of docetaxel and prednisolone for castration-resistant prostate cancer: a multi-institutional retrospective study in Japan.
Fukuta F; Kitamura H; Yanase M; Taguchi K; Takahashi A; Kunishima Y; Miyake M; Adachi H; Itoh N; Hirose T; Takagi S; Miyao N; Matsukawa M; Shigyo M; Masumori N
Jpn J Clin Oncol; 2015 Jul; 45(7):682-7. PubMed ID: 25862824
[TBL] [Abstract][Full Text] [Related]
26. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
Sun Z; Zhang N
World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
[TBL] [Abstract][Full Text] [Related]
27. Clinical application of serum tumor abnormal protein from patients with gastric cancer.
Liu J; Huang XE
Asian Pac J Cancer Prev; 2015; 16(9):4041-4. PubMed ID: 25987083
[TBL] [Abstract][Full Text] [Related]
28. A case of metastatic cancer with markedly elevated PSA level that was not detected by repeat prostate biopsy.
Iwamura H; Hatakeyama S; Tanaka Y; Tanaka T; Tokui N; Yamamoto H; Imai A; Yoneyama T; Hashimoto Y; Koie T; Yoshikawa K; Ohyama C
BMC Res Notes; 2014 Jan; 7():64. PubMed ID: 24476098
[TBL] [Abstract][Full Text] [Related]
29. [Prognostic value of serum CA(125) level change during chemotherapy post-surgery in patients with advanced epithelial ovarian carcinoma].
Lan CY; Huang H; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):732-6. PubMed ID: 19087537
[TBL] [Abstract][Full Text] [Related]
30. Permanent
Ding XF; Huang TB; Gao Y; Lu SM; Tao HZ; Xu JN; Xu YZ; Wang F; Zhou YQ; Zhou GC; Luan Y
Int J Urol; 2019 Feb; 26(2):278-283. PubMed ID: 30515888
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN
Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038
[TBL] [Abstract][Full Text] [Related]
32. Platinum sensitivity in metastatic prostate cancer: does histology matter?
Humeniuk MS; Gupta RT; Healy P; McNamara M; Ramalingam S; Harrison M; George D; Zhang T; Wu Y; Armstrong AJ
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):92-99. PubMed ID: 29230006
[TBL] [Abstract][Full Text] [Related]
33. Bicalutamide 150 mg as secondary hormonal therapy for castration-resistant prostate cancer.
Qian SB; Shen HB; Cao QF; Zhang L; Chen YF; Qi J
Int Urol Nephrol; 2015 Mar; 47(3):479-84. PubMed ID: 25665794
[TBL] [Abstract][Full Text] [Related]
34. Prostate-Specific Antigen Flare Phenomenon During
De Vincentis G; Follacchio GA; Frantellizzi V; Liberatore M; Monteleone F; Cortesi E
Clin Genitourin Cancer; 2016 Oct; 14(5):e529-e533. PubMed ID: 27212044
[No Abstract] [Full Text] [Related]
35. Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer.
Milowsky MI; Galsky MD; Morris MJ; Crona DJ; George DJ; Dreicer R; Tse K; Petruck J; Webb IJ; Bander NH; Nanus DM; Scher HI
Urol Oncol; 2016 Dec; 34(12):530.e15-530.e21. PubMed ID: 27765518
[TBL] [Abstract][Full Text] [Related]
36. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.
Oh WK; Manola J; Bittmann L; Brufsky A; Kaplan ID; Smith MR; Kaufman DS; Kantoff PW
Urology; 2003 Jul; 62(1):99-104. PubMed ID: 12837431
[TBL] [Abstract][Full Text] [Related]
37. Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel.
Nuhn P; Vaghasia AM; Goyal J; Zhou XC; Carducci MA; Eisenberger MA; Antonarakis ES
BJU Int; 2014 Dec; 114(6b):E11-E17. PubMed ID: 24529213
[TBL] [Abstract][Full Text] [Related]
38. Clinico-pathologic characterisation of metastatic prostate cancer in the Radiotherapy and Oncology Department, Ahmadu Bello University Teaching Hospital, Zaria-Nigeria: 2006-2009.
Adewuyi SA; Mbibu NH; Samaila MO; Ketiku KK; Durosinmi-Etti FA
Niger Postgrad Med J; 2013 Mar; 20(1):45-51. PubMed ID: 23661210
[TBL] [Abstract][Full Text] [Related]
39. Simple risk assessment in prostate cancer patients treated with primary androgen deprivation therapy: The Korean Cancer Study of the Prostate risk classification.
Choi SY; Ryu J; You D; Hong JH; Ahn H; Kim CS
Int J Urol; 2019 Jan; 26(1):62-68. PubMed ID: 30238513
[TBL] [Abstract][Full Text] [Related]
40. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
